RENAL EFFECTS OF NEUTRAL ENDOPEPTIDASE INHIBITION IN EUVOLEMIC AND HYPERVOLEMIC RATS

被引:6
作者
SCOTT, JM [1 ]
BARCLAY, PL [1 ]
SHEPPERSON, NB [1 ]
机构
[1] PFIZER LTD,CENT RES,DEPT CARDIOVASC BIOL,SANDWICH CT13 9NJ,KENT,ENGLAND
关键词
CANDOXATRILAT; NEUTRAL ENDOPEPTIDASE INHIBITION; ANF (ATRIAL NATRIURETIC FACTOR); VOLUME EXPANSION; CGMP;
D O I
10.1016/0014-2999(93)90014-9
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Candoxatrilat is a potent and selective inhibitor of neutral endopeptidase (EC 3.4.24.11), the enzyme responsible for the degradation of atrial natriuretic factor (ANF). In these studies, the renal effects of candoxatrilat were investigated in euvolemic and hypervolemic anaesthetised rats. In euvolemic rats, candoxatrilat (675 mug/kg per h) had no effect on urine output, sodium and potassium excretion or urinary cyclic GMP excretion. However, in hypervolemic rats, the natriuretic and diuretic responses to volume expansion were markedly potentiated by the candoxatrilat infusion, with a concomitant increase in urinary cyclic GMP. Acute volume expansion was characterised by natriuresis, diuresis and increased levels of plasma ANF and cyclic GMP (1.5-fold and 2-fold increases respectively, when compared to cuvolemic rats). The results presented suggest that plasma ANF levels and volume status modulate responses to neutral endopeptidase inhibition. The development of the neutral endopeptidase inhibitor, candoxatrilat, provides the opportunity to exploit endogenous ANF effectively in disease states with elevated ANF.
引用
收藏
页码:91 / 97
页数:7
相关论文
共 28 条
  • [1] HEART-FAILURE AUGMENTS THE CARDIOVASCULAR AND RENAL EFFECTS OF NEUTRAL ENDOPEPTIDASE INHIBITION IN RATS
    TRIPPODO, NC
    GABEL, RA
    HARVEY, CM
    ASAAD, MM
    ROGERS, WL
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1991, 18 (03) : 308 - 316
  • [2] Effects of the neutral endopeptidase inhibitor thiorphan on cardiovascular and renal function in cirrhotic rats
    Park, KS
    Li, Y
    Zhang, Y
    Gerbes, AL
    Liu, H
    Swain, MG
    Lee, SS
    BRITISH JOURNAL OF PHARMACOLOGY, 2003, 139 (01) : 81 - 88
  • [3] CONCURRENT NEUTRAL ENDOPEPTIDASE AND ACE-INHIBITION IN EXPERIMENTAL HEART-FAILURE - RENAL AND HORMONAL EFFECTS
    HELIN, K
    SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION, 1993, 53 (08) : 843 - 851
  • [4] Enhanced natriuretic response to neutral endopeptidase inhibition in patients with moderate chronic renal failure
    Lipkin, GW
    Dawnay, ABS
    Harwood, SM
    Cattell, WR
    Raine, AEG
    KIDNEY INTERNATIONAL, 1997, 52 (03) : 792 - 801
  • [5] Effects of renal neutral endopeptidase inhibition on sodium excretion, renal hemodynamics and neurohormonal activation in patients with congestive heart failure
    Kimmelstiel, CD
    Perrone, R
    Kilcoyne, L
    Souhrada, J
    Udelson, J
    Smith, J
    deBold, A
    Griffith, J
    Konstam, MA
    CARDIOLOGY, 1996, 87 (01) : 46 - 53
  • [6] ACUTE HEMODYNAMIC-EFFECTS OF COMBINED INHIBITION OF NEUTRAL ENDOPEPTIDASE AND ANGIOTENSIN-CONVERTING ENZYME IN SPONTANEOUSLY HYPERTENSIVE RATS
    PHAM, I
    LEVY, B
    FOURNIEZALUSKI, MC
    POITEVIN, P
    ROQUES, BP
    MICHEL, JB
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 1995, 9 (02) : 153 - 160
  • [7] Acute and chronic neutral endopeptidase inhibition and the natriuretic response to acute volume expansion
    Scheuermann, M
    Dietz, R
    Willenbrock, R
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1998, 347 (2-3) : 245 - 252
  • [8] Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics
    Mangiafico, Sarah
    Costello-Boerrigter, Lisa C.
    Andersen, Ingrid A.
    Cataliotti, Alessandro
    Burnett, John C., Jr.
    EUROPEAN HEART JOURNAL, 2013, 34 (12) : 886 - 893
  • [9] In vivo inhibition of neutral endopeptidase enhances the diagnostic potential of truncated gastrin 111In-radioligands
    Kaloudi, Aikaterini
    Nock, Berthold A.
    Lymperis, Emmanouil
    Sallegger, Werner
    Krenning, Eric P.
    de Jong, Marion
    Maina, Theodosia
    NUCLEAR MEDICINE AND BIOLOGY, 2015, 42 (11) : 824 - 832
  • [10] Protective effects of CGS 30440, a combined angiotensin-converting enzyme inhibitor and neutral endopeptidase inhibitor, in a model of chronic renal failure
    Cohen, DS
    Mathis, JE
    Dotson, RA
    Graybill, SR
    Wosu, NJ
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1998, 32 (01) : 87 - 95